Drug Topics September/October 2024

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

Recent research on vitamin D supplementation and respiratory tract infections can help guide pharmacists in counseling patients.

Current rules governing lawsuits must be revisited to strike a balance between legitimate and frivolous legal actions against health care providers.

Whether patients present with complaints of an aching muscle from a workout or a sudden twinge in the back, consider recommending these topical analgesics.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.

McKesson, Cardinal Health, and Cencora will share the settlement payment, resolving claims that the companies were significantly involved in fueling the US opioid epidemic.

Bezisterim acts on inflammatory signaling pathways and may be a viable treatment option for post–COVID-19 condition, or long COVID.

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around the importance of COVID-19 vaccines.

The National Association of Chain Drug Stores is active at both the federal and state levels in advocating for PBM reform.

A collaboration with Blue Cross and Blue Shield of North Carolina focused on commercial populations has improved care and lowered costs in the state.